Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Rheumatic Mitral Stenosis
NCT05618223Phase 3Unknown
- Sponsor
- Universitas Sebelas Maret
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dapagliflozin in rheumatic mitral stenosis (RMS) (2 arms), sponsored by Universitas Sebelas Maret. Primary endpoints: Carboxy-terminal propeptide of procollagen type I at 4 weeks, Matrix Metalloproteinase-1 at 4 weeks and 5 more. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
rheumatic mitral stenosis (RMS)
Beyond the preview
Go deeper on NCT05618223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618223.